Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Iran J Allergy Asthma Immunol. 2020 Aug 25;19(4):416-425. doi: 10.18502/ijaai.v19i4.4116.
T helper type 1 (Th1) and Th17 Cells with distinct cytokine profiles including interferon-gamma (IFN-γ) and interleukin 17 (IL-17) have a pivotal role in neuroinflammation and myelin destruction in the central nervous system (CNS) in MS. MicroRNA-29b (MiR-29b) and miR-326 contribute to regulating Th1 and Th17 differentiation and altered expression of the miRNAs could be associated with response to treatment in multiple sclerosis (MS). Therefore, our study aimed to evaluate the percentage of Th1 and Th17 and determining the expression levels of miR-29b-3p and miR-326 in these lymphocyte subpopulations between responsive and non-responsive to interferon beta (IFN-β) therapy in relapsing-remitting multiple sclerosis (RRMS) patients. The present study was performed on 40 RRMS patients following treatment with IFN-β. The percentage of Th1 cells and Th17 cells were determined by flow cytometry in responsive and non-responsive patients. The expression levels of miR-29b-3p and miR-326 were assessed in Th1 and Th17 cells by quantitative polymerase chain reaction (PCR). Enzyme-linked immunosorbent assay (ELISA) was applied to evaluate the plasma levels of IFN-γ and IL-17A. No significant difference was observed in the percentage of Th1 and Th17 cells as well as the expression levels of miR-29b-3p and miR-326 (in Th1 and Th17, respectively) in treated patients. Also, we did not find any significant difference in IFN-γ and IL-17A plasma concentration between responsive or non-responsive to IFN-β therapy in patients with RRMS. IFN-β may regulate other miRNAs in Th1 and Th17 cells than miR29b-3p and miR-326 in MS patients.
辅助性 T 细胞 1（Th1）和 Th17 细胞具有不同的细胞因子谱，包括干扰素-γ（IFN-γ）和白细胞介素 17（IL-17），在多发性硬化症（MS）的中枢神经系统（CNS）的神经炎症和髓鞘破坏中起关键作用。MicroRNA-29b（MiR-29b）和 miR-326 有助于调节 Th1 和 Th17 分化，miRNA 的异常表达可能与多发性硬化症（MS）的治疗反应有关。因此，我们的研究旨在评估对干扰素-β（IFN-β）治疗有反应和无反应的复发缓解型多发性硬化症（RRMS）患者中 Th1 和 Th17 的百分比，并确定这些淋巴细胞亚群中 miR-29b-3p 和 miR-326 的表达水平。本研究对 40 例接受 IFN-β 治疗的 RRMS 患者进行了研究。通过流式细胞术在有反应和无反应的患者中确定 Th1 细胞和 Th17 细胞的百分比。通过定量聚合酶链反应（PCR）评估 Th1 和 Th17 细胞中 miR-29b-3p 和 miR-326 的表达水平。应用酶联免疫吸附试验（ELISA）评估 IFN-γ和 IL-17A 的血浆水平。在接受治疗的患者中，Th1 和 Th17 细胞的百分比以及 miR-29b-3p 和 miR-326 的表达水平（分别在 Th1 和 Th17 细胞中）均无显著差异。此外，我们在 RRMS 患者对 IFN-β 治疗有反应或无反应的患者中，也未发现 IFN-γ和 IL-17A 血浆浓度有任何显著差异。IFN-β 可能在 MS 患者的 Th1 和 Th17 细胞中调节其他 miRNA，而不是 miR29b-3p 和 miR-326。
